Author:
Shoaf Susan E.,Bricmont Patricia,Mallikaarjun Suresh
Publisher
Dustri-Verlgag Dr. Karl Feistle
Subject
Pharmacology (medical),Pharmacology
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure ― A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial ―;Circulation Journal;2021-09-11
2. Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at BCRP, OATP1B1, and OAT3 transporters;Clinical and Translational Science;2021-04-09
3. Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity;Clinical Pharmacology & Therapeutics;2020-09-08
4. Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients;Basic & Clinical Pharmacology & Toxicology;2019-11-15
5. Validated liquid chromatography coupled to tandem mass spectrometry method for simultaneous quantitation of tolvaptan and its five major metabolites in human plasma;Annals of Clinical Biochemistry: International Journal of Laboratory Medicine;2019-03-04